PMID- 34778077
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211117
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current 
      Therapies, Challenges and Future Prospective.
PG  - 758512
LID - 10.3389/fonc.2021.758512 [doi]
LID - 758512
AB  - Haploidentical stem cell transplantation (haplo-SCT), an alternative donor 
      source, offers a curative therapy for patients with acute myeloid leukemia (AML) 
      who are transplant candidates. Advances in transplantation techniques, such as 
      donor selection, conditioning regimen modification, and graft-versus-host disease 
      prophylaxis, have successfully improved the outcomes of AML patients receiving 
      haplo-SCT and extended the haploidentical transplant indictions for AML. 
      Presently, treating de novo AML, secondary AML, therapy-related AML and 
      refractory and relapsed AML with haplo-SCT can achieve comparable outcomes to 
      those of human leukocyte antigen (HLA)-matched sibling donor transplantation 
      (MSDT), unrelated donor transplantation or umbilical cord blood transplantation. 
      For some subgroups of AML subjects, such as patients with positive 
      pretransplantation minimal/measurable residual disease, recent studies suggest 
      that haplo-SCT might be superior to MSDT in decreasing relapse and improving 
      survival. Unfortunately, for patients with AML after haplo-SCT, relapse and 
      infections remain the causes of death that restrict further improvement in 
      clinical outcomes. In this review, we discuss the recent advances and challenges 
      in haplo-SCT for AML treatment, mainly focusing on unmanipulated haplo-SCT 
      protocols. We provide an outlook on future prospects and suggest that relapse 
      prophylaxis, intervention, and treatment, as well as infection prevention and 
      therapy, are areas of active research in AML patients who receive haploidentical 
      allografts.
CI  - Copyright (c) 2021 Chang, Zhao and Huang.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Peking University Institute of Hematology, Peking University People's Hospital, 
      Beijing, China.
AD  - National Clinical Research Center for Hematologic Disease, Beijing, China.
AD  - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
AD  - Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
FAU - Zhao, Xiang-Yu
AU  - Zhao XY
AD  - Peking University Institute of Hematology, Peking University People's Hospital, 
      Beijing, China.
AD  - National Clinical Research Center for Hematologic Disease, Beijing, China.
AD  - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
AD  - Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Peking University Institute of Hematology, Peking University People's Hospital, 
      Beijing, China.
AD  - National Clinical Research Center for Hematologic Disease, Beijing, China.
AD  - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
AD  - Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211028
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8581046
OTO - NOTNLM
OT  - acute myeloid leukemia
OT  - graft-versus-leukemia-effect
OT  - haploidentical stem cell transplantation
OT  - infection
OT  - relapse
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/11/16 06:00
MHDA- 2021/11/16 06:01
PMCR- 2021/01/01
CRDT- 2021/11/15 07:08
PHST- 2021/08/14 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/11/15 07:08 [entrez]
PHST- 2021/11/16 06:00 [pubmed]
PHST- 2021/11/16 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.758512 [doi]
PST - epublish
SO  - Front Oncol. 2021 Oct 28;11:758512. doi: 10.3389/fonc.2021.758512. eCollection 
      2021.